3Lockman S, Kruuner A, Binkin N, et al. Clinical outcomes of Estonian patients with primary multidrug-resistant versus drug-susceptible tuberculosis [J] .Clin Infect Dis,2001,32(3) :373 - 380.
4WHO. WHO Report 2002, Global Tuberculosis Control [ M ]. Geneva,2002:1 - 3
5Cohn DL, Bustreo F, Ravigilione MC, et al. Drug resistant tuberculosis:review of worldwide situation and the WHO/IUATLD global surveillance project[J]. Clin Infect Dis, 1997,24:121 -130
6World Health Organization/International Union Against Tuberculosis and Lung Diseases. Guidelines for surveillance of drug resistance in tuberculosis[M]. Geneva: WHO,1997:2-12
8Carlo G,Vittoria P.Use of rifabutin in the treatment of pulmonary tuberculosis[J].Clin Infect,1996,22 (Suppl 1):S50
9Goldberg S V,Hanson D,Peloquin C A.Rifamycin treatment of tuberculosis in a patient receiving atenolol:less interaction with rifabutin than with rifampin[J].Clin Infect Dis,2003,37:607
10Aziz MA,Wright A.The World Health Organization/International Union Against Tuberculosis and Lung Disease Global Project on Surveillance for Anti-Tuberculosis Drug Resistance:a model for other infectious diseases.Clin Infect Dis,2005,41 Suppl 4:S258-S262.
9San J R ,Garcia-Reyne A ,Caba P ,et al. Safety and efficacy of moxifloxacin monotherapy for treatment of orthopedic implant-related staphylococcal in{ections [ J ]. Antimicrob Agents Chemother, 2010,54 ( 12 ) : 5161.
10Gould J W, Mercurio M G, Elmets C A. IEutaneous photosensitivity disease induced by exogenous agents [J]. J Am Acad Dermato1,1995(33):551.
